about
Transient ischaemic attack and ischaemic stroke: constructing episodes of care using hospital claims data.Investigation of HTR3C mutations for association with 5HT(3) receptor antagonist anti-emetic efficacy.Use of secondary stroke prevention medicines in Australia: national trends, 2003-2009.The use of antipsychotics among people treated with medications for dementia in residential aged care facilities.Medicines taken by older Australians after transient ischaemic attack or ischaemic stroke: a retrospective database study.Safety considerations of biosimilarsAcute opioid administration induces hypothalamic-pituitary-adrenal activation and is mediated by genetic variation in interleukin (Il)1B.Doubling in use of alteplase in Australia between 2003 and 2009.Antithrombotic use following transient ischaemic attack or ischaemic stroke among older Australians with atrial fibrillation.How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.Current Challenges and Potential Opportunities for the Pharmaceutical Sciences to Make Global Impact: An FIP Perspective.Effect of Garlic, Gingko, and St. John's Wort Extracts on the Pharmacokinetics of Fexofenadine: A Mechanistic Study.Pharmacogenomics in a Global World: A Roadmap for Australia, Prospects and ChallengesCYP2C19-guided design of a proton pump inhibitor dose regimen to avoid the need for pharmacogenetic individualisation in H. pylori eradicationReal-world incidence of patient-reported dyspnoea with ticagrelor
P50
Q30610734-FC914A5F-B173-4888-90CD-5821CF11D995Q34804496-96A66B1B-47C5-4C5B-A899-72A4FD719DA7Q38226857-53AB31D7-7A30-4933-A653-F2CEBFD7BA19Q40099193-A93C5D12-A7E2-49CD-98AC-FE47890F780CQ41003560-C615F595-C489-46E6-8309-E93D0E9DF5C0Q42353230-8177CE1C-850B-4425-BDFD-72473A8D73F1Q44332111-73EF360D-4B25-4B8F-A1F1-99D569781CB1Q45350984-08E4F5E5-2923-4D14-9F93-E85657DE94C0Q45958664-4C266B4A-7E17-4121-9EC4-80A33B711848Q48826707-33A84779-0C88-4325-B291-6498C1A2ADDCQ48865200-C2A95032-88E2-4A98-A905-93A4E8DBECFAQ51141618-A1EFA0DE-7253-496E-A773-35A0AF227505Q56332416-1A12A208-B150-4F62-B032-D2A3210C8F6CQ56332424-1914D3B2-4276-4BB2-A30A-EF72749BED2CQ57134527-7C199A64-D583-4B77-B0D4-2213401B1CDE
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Michael B. Ward
@ast
Michael B. Ward
@en
Michael B. Ward
@es
Michael B. Ward
@nl
Michael B. Ward
@sl
type
label
Michael B. Ward
@ast
Michael B. Ward
@en
Michael B. Ward
@es
Michael B. Ward
@nl
Michael B. Ward
@sl
prefLabel
Michael B. Ward
@ast
Michael B. Ward
@en
Michael B. Ward
@es
Michael B. Ward
@nl
Michael B. Ward
@sl
P1053
A-9263-2011
P106
P1153
56067919100
P2031
1993-01-01T00:00:00Z
P21
P31
P3829
P496
0000-0001-5121-5827